Drug project high-priority medications: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 16: Line 16:


==List of high-priority medications==
==List of high-priority medications==
===Novel Drug Approvals for 2021===
===Novel Drug Approvals for 2020===
===Novel Drug Approvals for 2019===
{| class="wikitable"
! No. !! Drug Name !! Active Ingredient !! Approval Date !! FDA-approved use on approval date
|-
| 48 || Ubrelvy || ubrogepant || 12/23/2019 || to treat acute treatment of migraine with or without aura in adults
|-
| 47 || Enhertu || fam-trastuzumab deruxtecan-nxki || 12/20/2019 || To treat metastatic breast cancer
|-
| 46 || Dayvigo || lemborexant || 12/20/2019 || To treat insomnia
|-
| 45 || Caplyta || lumateperone tosylate || 12/20/2019 || To treat schizophrenia
|-
| 44 || TissueBlue || Brilliant Blue G Ophthalmic Solution || 12/20/2019 || Dye used in eye surgery
|-
| 43 || Padcev || enfortumab vedotin-ejfv || 12/18/2019 || To treat refractory bladder cancer
|-
| 42 || Vyondys 53 || golodirsen || 12/12/2019 || To treat certain patients with Duchenne muscular dystrophy
|-
| 41 || Oxbryta || voxelotor || 11/25/2019 || To treat sickle cell disease
|-
| 40 || Xcopri || cenobamate || 11/21/2019 || To treat partial onset seizures
|-
| 39 || Givlaari || givosiran || 11/20/2019 || To treat acute hepatic porphyria, a rare blood disorder
|-
| 38 || Adakveo || crizanlizumab-tmca || 11/15/2019 || To treat patients with painful complication of sickle cell disease
|-
| 37 || Fetroja || cefiderocol || 11/14/2019 || To treat patients with complicated urinary tract infections who have limited or no alternative treatment options
|-
| 36 || Brukinsa || zanubrutinib || 11/14/2019 || To treat certain patients with mantle cell lymphoma, a form of blood cancer
|-
| 35 || Reblozyl || luspatercept–aamt || 11/8/2019 || For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions
|-
| 34 || ExEm Foam || air polymer-type A || 11/7/2019 || A diagnostic agent used to assess fallopian tube patency (openness) in women with known or suspected infertility
|-
| 33 || Trikafta || elexacaftor/ivacaftor/tezacaftor || 10/21/2019 || To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis
|-
| 32 || Reyvow || lasmiditan || 10/11/2019 || For the acute treatment of migraine with or without aura, in adults
|-
| 31 ||  || fluorodopa F 18 || 10/10/2019 || A diagnostic agent for use in positron emission tomography (PET) to help diagnose adult patients with suspected Parkinsonian syndromes (PS)
|-
| 30 || Scenesse || afamelanotide || 10/8/2019 || To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria
|-
| 29 || Beovu || brolucizumab–dbll || 10/7/2019 || Treatment of wet age-related macular degeneration
|-
| 28 || Aklief || trifarotene || 10/4/2019 || For the topical treatment of acne vulgaris in patients 9 years of age and older
|-
| 27 || Ibsrela || tenapanor || 9/12/2019 || To treat irritable bowel syndrome with constipation in adults.
|-
| 26 || Nourianz || istradefylline || 8/27/2019 || To treat adult patients with Parkinson’s disease experiencing “off” episodes
|-
| 25 || Ga-68-DOTATOC || Ga-68-DOTATOC || 8/21/2019 || For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs)
|-
| 24 || Xenleta || lefamulin || 8/19/2019 || To treat adults with community-acquired bacterial pneumonia
|-
| 23 || Rinvoq || upadacitinib || 8/16/2019 || To treat adults with moderately to severely active rheumatoid arthritis
|-
| 22 || Inrebic || fedratinib || 8/16/2019 || To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
|-
| 21 || Rozlytrek || entrectinib || 8/15/2019 || To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
|-
| 20 || Wakix || pitolisant || 8/14/2019 || To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy
|-
| 19 ||  || pretomanid || 8/14/2019 || For treatment-resistant forms of tuberculosis that affects the lungs
|-
| 18 || Turalio || pexidartinib || 8/2/2019 || To treat adult patients with symptomatic tenosynovial giant cell tumor
|-
| 17 || Nubeqa || darolutamide || 7/30/2019 || To treat adult patients with non-metastatic castration resistant prostate cancer
|-
| 16 || Accrufer || ferric maltol || 7/25/2019 || To treat iron deficiency anemia in adults
|-
| 15 || Recarbrio || imipenem, cilastatin and relebactam || 7/16/2019 || To treat complicated urinary tract and complicated intra-abdominal infections
|-
| 14 || Xpovio || selinexor || 7/3/2019 || To treat adult patients with relapsed or refractory multiple myeloma (RRMM)
|-
| 13 || Vyleesi || bremelanotide || 6/21/2018 || To treat hypoactive sexual desire disorder in premenopausal women.
|-
| 12 || Polivy || polatuzumab vedotin-piiq || 6/10/2019 || To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
|-
| 11 || Piqray || alpelisib || 5/24/2019 || To treat breast cancer
|-
| 10 || Vyndaqel || tafamidis meglumine || 5/3/2019 || To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults
|-
| 9 || Skyrizi || risankizumab-rzaa || 4/23/2019 || To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
|-
| 8 || Balversa || erdafitinib || 4/12/2019 || To treat adult patients with locally advanced or metastatic bladder cancer
|-
| 7 || Evenity || romosozumab-aqqg || 4/9/2019 || To treat osteoporosis in postmenopausal women at high risk of fracture
|-
| 6 || Mayzent || siponimod || 3/26/2019 || To treat adults with relapsing forms of multiple sclerosis
|-
| 5 || Sunosi || solriamfetol || 3/20/2019 || To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
|-
| 4 || Zulresso || brexanolone || 3/19/2019 || To treat postpartum depression (PPD) in adult women
|-
| 3 || Egaten || triclabendazole || 2/13/2019 || To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”
|-
| 2 || Cablivi || caplacizumab-yhdp || 2/6/2019 || To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP)
|-
| 1 || Jeuveau || prabotulinumtoxinA-xvfs || 2/1/2019 || For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients
|}


{| class="wikitable"
{| class="wikitable"

Revision as of 22:02, 11 November 2021

   Mission Statement   
   Tutorial   
   Editor's Checklist   

WikiDoc Drug Project — High-Priority Medications

List of high-priority medications

Novel Drug Approvals for 2021

Novel Drug Approvals for 2020

Novel Drug Approvals for 2019

No. Drug Name Active Ingredient Approval Date FDA-approved use on approval date
48 Ubrelvy ubrogepant 12/23/2019 to treat acute treatment of migraine with or without aura in adults
47 Enhertu fam-trastuzumab deruxtecan-nxki 12/20/2019 To treat metastatic breast cancer
46 Dayvigo lemborexant 12/20/2019 To treat insomnia
45 Caplyta lumateperone tosylate 12/20/2019 To treat schizophrenia
44 TissueBlue Brilliant Blue G Ophthalmic Solution 12/20/2019 Dye used in eye surgery
43 Padcev enfortumab vedotin-ejfv 12/18/2019 To treat refractory bladder cancer
42 Vyondys 53 golodirsen 12/12/2019 To treat certain patients with Duchenne muscular dystrophy
41 Oxbryta voxelotor 11/25/2019 To treat sickle cell disease
40 Xcopri cenobamate 11/21/2019 To treat partial onset seizures
39 Givlaari givosiran 11/20/2019 To treat acute hepatic porphyria, a rare blood disorder
38 Adakveo crizanlizumab-tmca 11/15/2019 To treat patients with painful complication of sickle cell disease
37 Fetroja cefiderocol 11/14/2019 To treat patients with complicated urinary tract infections who have limited or no alternative treatment options
36 Brukinsa zanubrutinib 11/14/2019 To treat certain patients with mantle cell lymphoma, a form of blood cancer
35 Reblozyl luspatercept–aamt 11/8/2019 For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions
34 ExEm Foam air polymer-type A 11/7/2019 A diagnostic agent used to assess fallopian tube patency (openness) in women with known or suspected infertility
33 Trikafta elexacaftor/ivacaftor/tezacaftor 10/21/2019 To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis
32 Reyvow lasmiditan 10/11/2019 For the acute treatment of migraine with or without aura, in adults
31 fluorodopa F 18 10/10/2019 A diagnostic agent for use in positron emission tomography (PET) to help diagnose adult patients with suspected Parkinsonian syndromes (PS)
30 Scenesse afamelanotide 10/8/2019 To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria
29 Beovu brolucizumab–dbll 10/7/2019 Treatment of wet age-related macular degeneration
28 Aklief trifarotene 10/4/2019 For the topical treatment of acne vulgaris in patients 9 years of age and older
27 Ibsrela tenapanor 9/12/2019 To treat irritable bowel syndrome with constipation in adults.
26 Nourianz istradefylline 8/27/2019 To treat adult patients with Parkinson’s disease experiencing “off” episodes
25 Ga-68-DOTATOC Ga-68-DOTATOC 8/21/2019 For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs)
24 Xenleta lefamulin 8/19/2019 To treat adults with community-acquired bacterial pneumonia
23 Rinvoq upadacitinib 8/16/2019 To treat adults with moderately to severely active rheumatoid arthritis
22 Inrebic fedratinib 8/16/2019 To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
21 Rozlytrek entrectinib 8/15/2019 To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
20 Wakix pitolisant 8/14/2019 To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy
19 pretomanid 8/14/2019 For treatment-resistant forms of tuberculosis that affects the lungs
18 Turalio pexidartinib 8/2/2019 To treat adult patients with symptomatic tenosynovial giant cell tumor
17 Nubeqa darolutamide 7/30/2019 To treat adult patients with non-metastatic castration resistant prostate cancer
16 Accrufer ferric maltol 7/25/2019 To treat iron deficiency anemia in adults
15 Recarbrio imipenem, cilastatin and relebactam 7/16/2019 To treat complicated urinary tract and complicated intra-abdominal infections
14 Xpovio selinexor 7/3/2019 To treat adult patients with relapsed or refractory multiple myeloma (RRMM)
13 Vyleesi bremelanotide 6/21/2018 To treat hypoactive sexual desire disorder in premenopausal women.
12 Polivy polatuzumab vedotin-piiq 6/10/2019 To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
11 Piqray alpelisib 5/24/2019 To treat breast cancer
10 Vyndaqel tafamidis meglumine 5/3/2019 To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults
9 Skyrizi risankizumab-rzaa 4/23/2019 To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
8 Balversa erdafitinib 4/12/2019 To treat adult patients with locally advanced or metastatic bladder cancer
7 Evenity romosozumab-aqqg 4/9/2019 To treat osteoporosis in postmenopausal women at high risk of fracture
6 Mayzent siponimod 3/26/2019 To treat adults with relapsing forms of multiple sclerosis
5 Sunosi solriamfetol 3/20/2019 To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
4 Zulresso brexanolone 3/19/2019 To treat postpartum depression (PPD) in adult women
3 Egaten triclabendazole 2/13/2019 To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”
2 Cablivi caplacizumab-yhdp 2/6/2019 To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP)
1 Jeuveau prabotulinumtoxinA-xvfs 2/1/2019 For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients



Year No. Brand Name Active Ingredient Page Link DailyMed Search Approval Date Status Author
2019 12 Polivy Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq Polivy 6/10/2019
2019 11 Piqray Alpelisib Alpelisib Piqray 5/24/2019 Needs review Uma Maveli
2019 10 Vyndaqel Tafamidis meglumine Tafamidis meglumine Vyndaqel 5/3/2019
2019 9 Skyrizi Risankizumab Risankizumab Skyrizi 4/23/2019
2019 8 Balversa Erdafitinib Erdafitinib Balversa 4/12/2019
2019 7 Evenity Romosozumab Romosozumab Evenity 4/9/2019
2019 6 Mayzent Siponimod Siponimod Mayzent 3/26/2019
2019 5 Sunosi Solriamfetol Solriamfetol Sunosi 3/20/2019
2019 4 Zulresso Brexanolone Brexanolone Zulresso 3/19/2019
2019 3 Egaten Triclabendazole Triclabendazole Egaten 2/13/2019
2019 2 Cablivi Caplacizumab Caplacizumab Cablivi 2/6/2019
2019 1 Jeuveau prabotulinum toxin type a powder prabotulinum toxin type a powder Jeuveau 2/1/2019
2018 59 Ultomiris Ravulizumab Ravulizumab Ultomiris 12/21/2018 Needs review Bhavya
2018 58 Elzonris Tagraxofusp-erzs Tagraxofusp-erzs Elzonris 12/21/2018
2018 57 Asparlas Calaspargase pegol-mknl Calaspargase pegol-mknl Asparlas 12/20/2018
2018 56 Motegrity Prucalopride Prucalopride Motegrity 12/14/2018
2018 55 Xospata Gilteritinib Gilteritinib Xospata 11/28/2018 Needs review Uma Maveli
2018 54 Firdapse Amifampridine Amifampridine Firdapse 11/28/2028
2018 53 Vitrakvi Larotrectinib Larotrectinib Vitrakvi 11/26/2018
2018 52 Daurismo Glasdegib Glasdegib Daurismo 11/21/2018 Need review Bhavya
2018 51 Gamifant Emapalumab-lzsgemapalumab-lzsg Emapalumab-lzsgemapalumab-lzsg Gamifant 11/20/2018
2018 50 Aemcolo Rifamycin Rifamycin Aemcolo 11/16/2018
2018 49 Yupelri Revefenacin Revefenacin Yupelri 11/9/2018 Needs review Uma Maveli
2018 48 Lorbrena Lorlatinib Lorlatinib Lorbrena 11/2/2018 Needs review Uma Maveli
2018 47 Xofluza Baloxavir marboxil Baloxavir marboxil Xofluza 10/24/2018
2018 46 Talzenna Talazoparib Talazoparib Talzenna 10/16/2018
2018 45 Tegsedi Inotersen Inotersen Tegsedi 10/5/2018
2018 44 Revcovi Elapegademase-lvlr Elapegademase-lvlr Revcovi 10/5/2018
2018 43 Nuzyra Omadacycline Omadacycline Nuzyra 10/2/2018
2018 42 Seysara Sarecycline Sarecycline Seysara 10/1/2018
2018 41 Libtayo Cemiplimab-rwlc Cemiplimab-rwlc Libtayo 9/28/2018
2018 40 Vizimpro Dacomitinib Dacomitinib Vizimpro 9/27/2018
2018 39 Emgality Galcanezumab-gnlm Galcanezumab-gnlm Emgality 9/27/2018
2018 38 Copiktra Duvelisib Duvelisib Copiktra 9/24/2018
2018 37 Ajovy Fremanezumab-vfrm Fremanezumab-vfrm Ajovy 9/14/2018
2018 36 Lumoxiti Moxetumomab pasudotox-tdfk Moxetumomab pasudotox-tdfk Lumoxiti 9/13/2018
2018 35 Pifeltro Doravirine Doravirine Pifeltro 8/30/2018
2018 34 Xerava Eravacycline Eravacycline Xerava 8/27/2018
2018 33 Takhzyro Lanadelumab Lanadelumab Takhzyro 8/23/2018
2018 32 Oxervate Cenegermin-bkbj Cenegermin-bkbj Oxervate 8/22/2018
2018 31 Diacomit Stiripentol Stiripentol Diacomit 8/20/2018
2018 30 Galafold Migalastat Migalastat Galafold 8/10/2018
2018 29 Annovera Segesterone acetate and ethinyl estradiol vaginal system Segesterone acetate and ethinyl estradiol vaginal system Annovera 8/10/2018
2018 28 Onpattro Patisiran Patisiran Onpattro 8/10/2018
2018 27 Poteligeo Mogamulizumab Mogamulizumab Poteligeo 8/8/2018
2018 26 Mulpleta Lusutrombopag Lusutrombopag Mulpleta 7/31/2018
2018 25 Omegaven Fish oil triglycerides Fish oil triglycerides Omegaven 7/27/2018 Bhavya In progress
2018 24 Orilissa Elagolix Elagolix Orilissa 7/23/2018
2018 23 Krintafel Tafenoquine Tafenoquine Krintafel 7/20/2018
2018 22 Tibsovo Ivosidenib Ivosidenib Tibsovo 7/20/2018
2018 21 TPOXX Tecovirimat Tecovirimat TPOXX 7/13/2018
2018 20 Braftovi Encorafenib Encorafenib Braftovi 6/27/2018
2018 19 Mektovi Binimetinib Binimetinib Mektovi 6/27/2018
2018 18 Zemdri Plazomicin Plazomicin Zemdri 6/25/2018
2018 17 Epidioloex Cannabidiol Cannabidiol Epidioloex 6/25/2018
2018 16 Moxidectin Moxidectin Moxidectin Moxidectin 6/13/2018
2018 15 Olumiant Baricitinib Baricitinib Olumiant 5/31/2018
2018 14 Palynziq Pegvaliase-pqpz Pegvaliase-pqpz Palynziq 5/24/2018
2018 13 Doptelet Avatrombopag Avatrombopag Doptelet 5/21/2018
2018 12 Lokelma Sodium zirconium cyclosilicate Sodium zirconium cyclosilicate Lokelma 5/18/2018
2018 11 Aimovig Erenumab-aooe Erenumab-aooe Aimovig 5/17/2018
2018 10 Lucemyra Lofexidine hydrochloride Lofexidine hydrochloride Lucemyra 5/16/2018
2018 9 Akynzeo Fosnetupitant and palonosetron Fosnetupitant and palonosetron Akynzeo 4/19/2018
2018 8 Crysvita Burosumab-twza Burosumab-twza Crysvita 4/17/2018
2018 7 Tavalisse Fostamatinib Fostamatinib Tavalisse 4/17/2018
2018 6 Ilumya Tildrakizumab Tildrakizumab Ilumya 3/20/2018
2018 5 Trogarzo Ibalizumab-uiyk Ibalizumab-uiyk Trogarzo 3/6/2018
2018 4 Erleada Apalutamide Apalutamide Erleada 2/14/2018
2018 3 Symdeko Tezacaftor/ivacaftor Tezacaftor/ivacaftor Symdeko 2/12/2018
2018 2 Biktarvy Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate Biktarvy 2/7/2018
2018 1 Lutathera Lutetium lu 177 dotatate Lutetium lu 177 dotatate Lutathera 1/26/2018
Retrieved from "https://www.wikidoc.org/index.php?title=Drug_project_high-priority_medications&oldid=1716456"